1064 Background: In 11.2018, the PIK3CA-inhibitor alpelisib was made available in France through an early access program (EAP), in combination with fulvestrant in pre-treated PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer (ABC) patients. Patients had to received two or more prior systemic treatments for ABC, including an...
-
May 20, 2021 (v1)Journal articleUploaded on: December 3, 2022
-
April 2021 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
April 2020 (v1)Journal article
The impact of locoregional treatment (LRT) on overall survival (OS) in de novo metastatic breast cancer (dnMBC) is still under debate, with very few data available regarding exclusive radiotherapy (ERT) as a therapeutic modality.
Uploaded on: December 4, 2022 -
August 2022 (v1)Journal article
Background: In spite of the frequency and clinical impact of BRCA1/2 alterations in high-grade epithelial ovarian cancer (HGEOC), real-world information based on robust data warehouse has been scarce to date. Methods: Consecutive patients with BRCA-mutated HGEOC treated between 2011 and 2016 within French comprehensive cancer centers from the...
Uploaded on: November 25, 2023 -
February 2019 (v1)Journal article
International audience
Uploaded on: December 4, 2022